Collaborative and Other Relationships - Mosunetuzumab (Details) - Mosunetuzumab - USD ($) $ in Millions	1 Months Ended	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2021
Collaborative arrangements and non-collaborative arrangement transactions
Option exercise fee	$ 30.0
Development of product candidate expense		$ 20.0
Percentage of future development costs		30.00%
Minimum
Collaborative arrangements and non-collaborative arrangement transactions
Future percentage of co-promotion operating profits		30.00%
Maximum
Collaborative arrangements and non-collaborative arrangement transactions
Future percentage of co-promotion operating profits		37.50%